Effect of a Probiotic on the Urinary Tract Microbiota of Participants With Recurrent Urinary Tract Infection. (PROBUTI)
Recurrent Urinary Tract Infection
About this trial
This is an interventional treatment trial for Recurrent Urinary Tract Infection
Eligibility Criteria
Inclusion Criteria: Adult women with aged between 18 and 50 years old, diagnosed with recurrent UTI (defined as at least two episodes during the last six months or three during the last 12 months). Diagnosed, the last 72 hours, for a new UTI episode. Written informed consent signed. Exclusion Criteria: Menopausal Pregnant, breastfeeding or planning to become pregnant during the study. Congenital abnormalities of the urinary tract. Renal functional alterations, such as neurogenic bladder or vesicoureteral reflux. Relevant renal disorders, such as interstitial cystitis, renal lithiasis, renal failure, kidney transplantation, pyelonephritis, renal nephropathy, etc. Permanent catheter. Immunocompromised (eg: cancer and/or transplant, patients who are taking immunosuppressive drugs, patients with hereditary diseases that affect or may affect the immune system). Type I diabetes. With a defect in the intestinal epithelium barrier (eg: chronic diarrhea, inflammatory bowel disease). Heart failure and cardiac medical history (eg, artificial heart valve, medical history of infective endocarditis, rheumatic fever, or cardiac malformation). Under antibiotics prophylactic treatment without willingness to leave it at the time of inclusion. Probiotics supplementation during the previous 2 weeks. To have received Urovac, Uro-Vaxom or equivalent vaccine during the last year. Currently participating in another clinical trial.
Sites / Locations
- Hospital San Francisco de AsísRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Placebo Comparator
Probiotic
Probiotic + placebo
Placebo
2 Capsule daily containing approximately 1*10E9 colony forming unit (CFU) of Lactobacillus CECT 9422 +1*10E9 colony forming unit (CFU) of Bifidobacterium CECT 30257.
One capsule daily containing approximately 1*10E9 colony forming unit (CFU) of Lactobacillus CECT 9422 +1*10E9 colony forming unit (CFU) of Bifidobacterium CECT 30257 and 1 capsule of placebo supplement.
Two capsules daily of Placebo supplement.